Advaxis, Inc. (NASDAQ: ADXS) is the
biggest gainer in the collaboration with Amgen Inc. (NASDAQ: AMGN).
The companies struck a collaboration deal for the development, as well as, commercialization of ADXS-NEO meant for the treatment
of cancer immunotherapy. Amgen would get global rights to develop and commercialize the investigational drug by paying an upfront
payment of $40 million apart from buying Advaxis shares worth $25 million.
Advaxis would also have the potential of earning a maximum of $475 million with high single-digit to mid-double digit royalty
payments depending on the global sales.
Its president and CEO, Daniel O'Connor, said, "With Amgen's resources, worldwide reach and a culture that embraces science and
innovation, we are positioned to accelerate the clinical development program for ADXS-NEO to improve the lives of those who suffer
from cancer."
Volatility in the stock is nothing new to shareholders of the company. The most recent instance of sharp upside came at the
beginning of March when a company study was selected for a late-breaking poster at the American Association for Cancer Research.
Shares nearly doubled following the news, and ran from under $5.50 to over the $9 level.
The stock traded higher by $2.28 or 26.92 percent at $10.75 in the pre-market on Tuesday. Shares of the company resisted at
around $9.50 level in June before dropping down to below $8 level in July.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.